|
Focus on anthraxRecent events have confirmed that bioterrorism is no longer a threat but a reality. To provide wide-ranging access to the latest scientific information about anthrax and other potential bioweapons, Nature has put together a special online focus on this issue. This focus is made up of two research papers on anthrax toxin, as well as a collection of research, news and feature articles from our electronic archive. The causative agent of the anthrax disease, the bacterium Bacillus anthracis, secretes a toxin made up of three proteins: protective antigen (PA), oedema factor (OF) and lethal factor (LF). PA binds to cell-surface receptors on the host's cell membranes. After being cleaved by a protease, PA binds to the two toxic enzymes, OF and LA, and mediates their transportation into the cytosol where they exert their pathogenic effects. In addition to these Nature papers, this special focus also includes research from October's issue of Nature Biotechnology. Mourez et al. describe the isolation of a synthetic peptide that blocks the action of anthrax toxin in an animal model. These research papers are complimented by a news feature which looks at the threat of bioterrorism and researchers' attempts to counter it, and a collection of research, news and opinion articles from our archive. Nature's news and science-writing teams will continue to inform and explain the science behind current events as and when it happens, and this page will be updated accordingly. Featured articles Crystal
structure of the anthrax lethal factor Anthrax action shapes upAnthrax exposed and killed Designing a polyvalent inhibitor of
anthrax toxin Genomics and future biological weapons: the need for preventive
action by the biomedical community News & ViewsMedicine: Virus deals anthrax a killer blowM. J. ROSOVITZ & STEPHEN H. LEPPLA The threat of antibiotic-resistant bacteria is driving researchers to think up ever more clever ways to tackle infections. An enzyme from a bacterium-killing virus may prove effective against anthrax infections. Nature 418, 825-826 (22 August 2002) | Full Text | PDF (108 K) | Related newsAnthrax case provokes doubt among expertsJONATHAN KNIGHT & ERIKA CHECK Nature 418, 808 (22 August 2002) | Full Text | PDF (131 K) | Microbiology:
Tackling anthrax Bioterrorism threat becomes reality Smallpox vaccine development
quickened The bugs of war Genetic sleuths rush to identify
anthrax strains in mail attacks Bioweapons treaty under threat Gaps remain in Japan's biodefences Senators call for biodefence
boost Business News Pathogen threat spurs research initiatives Shock as labs miss anthrax samples Smallpox stocks: new focus for research? Adjusting FDA policies to address bioterrorist
threat Iraq crisis spurs new bioweapons moves Letters to NatureA bacteriolytic agent that detects and kills Bacillus anthracisRAYMOND SCHUCH, DANIEL NELSON & VINCENT A. FISCHETTI Nature 418, 884-889 (22 August 2002) | Full Text | PDF (1046 K) | Related researchA dominant-negative
therapy for anthrax Related commentary and opinionA
call to arms Lessons from Iraq on bioweapons
Related linksNature © Macmillan Publishers Ltd 2001 Registered No. 785998 England. | |